The balance sheet appears increasingly fragile, evidenced by a current ratio that plummeted to 0.29 in 2026Q1 and a retained earnings deficit of $44.1M.
Mangoceuticals, Inc. (MGRX) balance sheet — 5-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Total Current Assets | 245.69K | 1.55M | 75.59K | 818.46K | 694.61K | 22.55K |
| Cash & Short-Term Investments | 228.69K | 1.49M | 58.65K | 739.01K | 682.86K | 22.55K |
| Cash Only | 228.69K | 1.49M | 58.65K | 739.01K | 682.86K | 22.55K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 5.81 | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 18.5K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | 22.51 | - | - |
| Other Current Assets | 16.96K | 61.1K | 16.94K | 0 | 0 | 0 |
| Total Non-Current Assets | 13.93M | 14.54M | 15.29M | 232.33K | 308.68K | 0 |
| Property, Plant & Equipment | 280.54K | 309.65K | 62.3K | 215.39K | 291.74K | 0 |
| Fixed Asset Turnover | 1.40x | 1.47x | 9.89x | 3.40x | 0.03x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 13.65M | 14.23M | 15.23M | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 16.94K | 16.94K | 0 |
| Total Assets | 14.17M | 16.09M | 15.37M | 1.05M | 1M | 22.55K |
| Asset Turnover | 0.02x | 0.03x | 0.04x | 0.70x | 0.01x | - |
| Asset Growth % | -49.14% | 4.68% | 1362.75% | 4.74% | 4349.17% | - |
| Total Current Liabilities | 1.4M | 890.57K | 1.43M | 211.08K | 260.58K | 39.27K |
| Accounts Payable | 889.73K | 416.68K | 837.5K | 140.76K | 33.67K | 0 |
| Days Payables Outstanding | 1.5K | 739.61 | 1.3K | 171.27 | 3.01K | - |
| Short-Term Debt | 44.94K | 0 | 150K | 0 | 167.46K | 39.27K |
| Deferred Revenue (Current) | 275K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 373K | 0 | 0 | 0 |
| Current Ratio | 0.18x | 1.74x | 0.05x | 3.88x | 2.67x | 0.57x |
| Quick Ratio | 0.18x | 1.74x | 0.05x | 3.79x | 2.67x | 0.57x |
| Cash Conversion Cycle | -1.5K | - | - | - | - | - |
| Total Non-Current Liabilities | 250.91K | 0 | 0 | 64.96K | 128.68K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 487.87K | 0 | 0 | 64.96K | 128.68K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.65M | 890.57K | 1.43M | 276.04K | 389.26K | 39.27K |
| Total Debt | 324.15K | 307.82K | 214.96K | 128.68K | 352.87K | 39.27K |
| Net Debt | 95.46K | -1.18M | 156.31K | -610.33K | -330K | 16.72K |
| Debt / Equity | 0.03x | 0.02x | 0.02x | 0.17x | 0.57x | - |
| Debt / EBITDA | -0.03x | - | - | - | - | - |
| Net Debt / EBITDA | -0.01x | - | - | - | - | - |
| Interest Coverage | -22.58x | -198.43x | -634.60x | - | -307.68x | -96.80x |
| Total Equity | 12.52M | 15.2M | 13.95M | 774.75K | 614.03K | -16.72K |
| Equity Growth % | -41.91% | 8.99% | 1699.93% | 26.18% | 3772.43% | - |
| Book Value per Share | 0.73 | 1.51 | 7.05 | 0.54 | 0.53 | -0.01 |
| Total Shareholders' Equity | 12.53M | 15.2M | 13.95M | 774.75K | 614.03K | -16.72K |
| Common Stock | 1.8K | 1.59K | 325 | 2.14K | 1.34K | 800 |
| Retained Earnings | -45.36M | -40.65M | -20.81M | -11.23M | -2.02M | -17.7K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5.2K | -2.76K | -9.85K | 0 | 0 | 0 |
| Minority Interest | -2.12K | -1.54K | -1.08K | 0 | 0 | 0 |
Quick answers to the most common questions about buying MGRX stock.
As of 2025, Mangoceuticals, Inc. (MGRX) had total assets of $16.1M including $1.5M in current assets.
Mangoceuticals, Inc. (MGRX) carries total debt of $0.3M, offset by $1.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Mangoceuticals, Inc. (MGRX) has total shareholders' equity (book value) of $15.2M ($1.51 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Mangoceuticals, Inc. (MGRX) reported a current ratio of 1.74x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Insufficient liquidity for operations
Metrics are mathematically derived from official filings.
Balance Sheet Erosion and Instability
As reported in recent financial statements, MGRX has seen its total assets decline from a peak of $21.8M in 2025Q1 to $14.4M by 2026Q1, reflecting a persistent contraction that underscores the company's inability to stabilize its capital base amidst ongoing operational losses.
The consistent downward trend in total assets suggests that the company is consuming its resource base to fund operating deficits rather than investing in growth. Investors should monitor whether this trajectory indicates an impending exhaustion of the company's ability to support its current business model.
Goodwill Dominance Masks Asset Quality
Based on the provided balance sheet data, goodwill accounts for approximately 96% of total assets as of 2026Q1, which suggests that the company's asset base is heavily reliant on intangible valuations rather than tangible, revenue-generating infrastructure or liquid capital reserves.
The high concentration of goodwill relative to total assets implies a significant risk of future impairment charges, especially given the company's inability to achieve profitable scale. This asset composition provides little tangible support for creditors or shareholders in the event of a further downturn.
Precarious Liquidity and Cash Runway
According to quarterly filings, the current ratio has plummeted to 0.29 in 2026Q1, down from 1.74 in 2025Q4, indicating that the company's ability to meet its short-term obligations has deteriorated rapidly as cash reserves have been depleted to support ongoing operations.
A current ratio well below 1.0 suggests that current liabilities significantly outweigh liquid assets, creating a high risk of a liquidity crunch. The rapid decline in cash levels warrants further investigation into the company's ability to maintain operations without immediate external financing.
Equity Erosion and Capital Dilution
As evidenced by the historical data, retained earnings have deepened to a deficit of $44.1M by 2026Q1, signaling that years of negative profitability have severely eroded the company's equity base and left shareholders with a diminished claim on the firm's net assets.
The persistent accumulation of losses in retained earnings suggests that the business model has failed to generate value for shareholders since inception. This trend may necessitate further dilutive equity raises, which would likely exacerbate the pressure on existing equity holders.